Abstract
The development of safe and effective anti-inflammatory dosage forms for children is one of the most important areas of modern pharmaceutical science. Among nonsteroidal anti-inflammatory drugs, meloxicam is among the most commonly used substances in clinical practice. Objective. To study the preclinical toxicity and anti-inflammatory activity of meloxicam tablets for children (coated, prolonged effects, special dose). Methods and materials: acute toxicity in animals was determined, as well as an assessment of specific pharmacological activity in models of histamine-induced and carrageenan aseptic inflammation. Study results: The study showed that Meloxicam tablets for children are non-toxic and have greater anti-inflammatory activity than the comparison drug. The study on the specific activity of Meloxicam 3.75 mg tablets for children + cyanocobalamin 0.002 mg demonstrated their high anti-inflammatory activity in experimental aseptic inflammation models. This indicates an increased anti-inflammatory effect of meloxicam when combined with cyanocobalamin. Conclusion: the results showed that the anti–inflammatory activity of the studied drug, meloxicam children’s tablets, is higher than that of the comparative drug meloxicam.